Share icon Three circles with dashes Person icon Man with pen You Tube Logo Just "You tube" text Facebook logo Small letter f Search icon Magnifier Twitter logo Simplified small bird Email icon Envelope
Skip to main

The Weizmann Institute of Science and Pfizer Enter Agreement

The multi-year agreement places a visiting Pfizer scientist in the Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM), with a yearly rotation.

In June, 2016, the Weizmann Institute of Science in Rehovot, Israel, and Yeda Research and Development Co., Ltd., its commercial arm entered a multi-year arrangement with Pfizer Inc. The arrangement entails collaboration at the newly established Institute for Medicinal Chemistry (IMC) in the Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM), which is part of the Weizmann Institute and located on its campus. The IMC is a part of one of four units in the G-INCPM, the Maurice and Vivienne Wohl Institute for Drug Discovery. Pfizer will be supporting the G-INCPM by placing a Pfizer medicinal chemist (rotating on a yearly basis) at the Institute to assist with advancing target selection and high-throughput screening, as well as leading development campaigns for programs that enter the IMC.  If projects of mutual interest — those that hold promise in addressing unmet medical needs — are identified, Pfizer and Yeda will evaluate the potential for research and development agreements.

“We are very pleased to collaborate with Pfizer, and to work side-by-side with its scientists in our new national center, to build a world-class discovery and medicinal chemistry organization,” said Dr. Berta Strulovici, Head of the G-INCPM. “We welcome Pfizer’s commitment to scientific discovery, and we are excited to host Pfizer scientists on campus and to broaden the potential impact of our joint efforts and common aim to discover new medicines that may benefit patients around the world.”

Amir Naiberg, CEO of Yeda, added: “We are pleased to announce this collaboration with Pfizer. Pfizer’s presence in the Weizmann Institute campus will give Pfizer potential access to Israeli innovation and allow Israeli scientists at the Weizmann Institute to enjoy direct access to the drug development expertise of Pfizer medicinal chemists.”

“This is an exciting partnership for Pfizer,” said Mikael Dolsten, President of Pfizer Global Research.  “We have interacted with the Weizmann Institute for many years and have confidence in their scientific vision and expertise. We anticipate that this arrangement could potentially result in meaningful discoveries in the coming years. We look forward to working with many Israeli scientists and to seeing the outcomes of this effort.”

This article originally appeared on Weizmann Wonder Wander under the title: Weizmann Institute of Science Announces Visiting Scientist Agreement with Pfizer Inc.

____________________________________________________________________________________________________________________________

Israel BDS – building dialogue through science – aims to promote the kind of international collaboration that can lead to true understanding between people. Israel BDS stands for the free and open exchange of ideas among scientists everywhere. By reporting on the benefits of Israeli-international scientific research and the web of connections that these scientists create around the world, Israel BDS takes a vibrant approach to highlighting the global necessity of continued international scientific collaboration.

___________________________________________________________________________________________________________________________

Lefker

Dr. Bruce Lefker of Pfizer and Dr. Berta Strulovici, head of the G-INCPM, on the Weizmann campus